jeudi 2 novembre 2017

Onco Actu du 2 novembre 2017

2.6 Etiologie - Environnement

Exclusive: Congressional committee questions operation of WHO cancer agency [Reuters]

3.1 Prévention - Tabac

Tobacco firms using 'clever tactics' to target poorest smokers, study finds [The Guardian]

3.2 Prévention - Obésité

Recommendations from ASCO Summit Promotes Multi-disciplinary Collaboration to Focus on Obesity Prevention and Treatment [ASCO]

3.4.1 Chimioprévention - aspirine

An aspirin a day keeps many cancers away, study suggests [The Telegraph]

4. Dépistage, diagnostic et pronostic

Is there a conflict of interest behind your cancer diagnosis? [STAT]

4.11 Dép., diag. & prono. - Ovaire

New Blood Test Developed to Diagnose Ovarian Cancer [Dana-Farber Cancer Institute]

4.2 Dép., diag. & prono. - Génome

3 Lessons From An Alarming Case Of Mistaken Cancer Gene Test Results And Surgery [Forbes]

Genomic studies track early hints of cancer [Nature]

4.9 Dép., diag. & prono. - Sein

TMIST Trial Aims to Provide Clarity on Breast Cancer Screening Approaches [NCI]

EndoPredict (EPclin) Shown in Second Study to be More Effective than Oncotype DX® (RS) in Women with Intermediate Risk of Breast Cancer Recurrence [Myriad]

The Mammography Quality Standards Act – a 25-year Public Health Success Story [FDA Voice]

Uruguay’s mandatory breast cancer screening is challenged [BMJ Blogs]

5. Traitements

Watch Your Covalent Drugs Carefully [In the Pipeline]

5.1 Traitements - Pré-clinique

Researchers find fatal flaw in childhood tumors [Science]

Sight Unseen [Harvard Medical School]

5.12.1 Immunothérapies - partenariats

PhIII dealmaking frenzy in i/o continues as AstraZeneca follows PACIFIC with a new Incyte IDO1 combo [EndPoints]

AstraZeneca and Incyte enter clinical trial collaboration in early lung cancer [AstraZeneca]

5.12.2 Immunothérapies - CAR-T

Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy [Novartis]

Novartis asks FDA to expand Kymriah's use against blood cancer [Reuters]

5.12.3 Immunothérapies-combinaisons

Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy [Boehringer Ingelheim]

5.12.5 Immunothérapies - Pharma

Bristol-Myers Squibb could double patient numbers for Opdivo in kidney cancer [FiercePharma]

European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) for Treatment of Patients with Resected High-Risk Advanced Melanoma [BMS]

Merck Has Good Reasons for Its Keytruda Delay [Bloomberg]

Merck Keytruda sales soar, but European application pulled [Reuters]

Merck Provides Update on European Application for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Carboplatin for First-Line Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC) [Merck]

5.12.8 Immunothérapies - Economie

UK's NICE gives Roche drug green light for bladder cancer [Reuters]

5.2 Pharma

Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma [Seattle Genetics]

GSK’s investigational BCMA antibody-drug conjugate receives Breakthrough Therapy Designation from US FDA for relapsed and refractory multiple myeloma [GSK]

5.2.1 Pharma - Partenariats

Public-private consortium aims to cut preclinical cancer drug discovery from six years to just one [GSK]

5.2.2 Pharma - Fusions & Acquisitions

Novartis snags blockbuster hopeful Lutathera in $3.9B deal for Advanced Accelerator [FiercePharma]

Novartis Looks to Buy French Firm to Bolster Cancer Portfolio [NY Times]

Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio [Novartis]

Novartis builds cancer pipeline with a new platform/drug buyout, bagging Advanced Accelerator Applications for $3.9B [EndPoints]

In a switch, Merck CEO signals he’s in a deal-making frame of mind [EndPoints]

5.2.3 Pharma - économie

Roche pulls cancer drug from Greece in fight over government cost cuts [FiercePharma]

5.3 Traitements - FDA, EMA, NICE...

EU-US mutual recognition of inspections of medicines manufacturers enters operational phase [EMA]

5.3.4 Traitements - AMM (FDA, EMA)

US FDA approves AstraZeneca’s Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma [AstraZeneca]

FDA approves new treatment for adults with mantle cell lymphoma [FDA]

Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-Dilute [Eagle]

Eagle Pharma gets tentative FDA approval for Lilly's Alimta version [Reuters]

AstraZeneca wins early U.S. approval for blood cancer drug [Reuters]

5.4 Traitements - Economie

Value-Based Contracting for Oncology Drugs: A NEHI White Paper [NEHI]

Rapid flurry of new drug pricing leaves no room for public debate [The Hill]

5.8.2 ASH - Pharma

ImmunoGen to Present New Data on Novel Antibody-Drug Conjugates at 59th ASH Annual Meeting [ImmunoGen]

Seattle Genetics to Present Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program at ASH 2017 [Seattle Genetics]

Juno Therapeutics to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASH [Juno]

ASH 2017: Janssen to Present 40 Abstracts, Including 8 Oral Presentations, with New Data on DARZALEX® (daratumumab), IMBRUVICA® (ibrutinib) and Other Compounds from Robust Portfolio [Janssen]

Genmab Announces Data to be Presented at 2017 ASH Annual Meeting [Genmab]

Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting [Roche]

5.8.4 ASH - CAR T

ASH Sneak Peeks: Novartis, Juno Update CAR-T Lymphoma Competition [Xconomy]

Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting [Cellectis]

Cellectis Announces Two Oral Presentations and One Poster Presentation at the 2017 ASH Annual Meeting [Cellectis]

#ASH17: Novartis’ 6-month Kymriah data in DLBCL sets up a head-to-head fight with Gilead [EndPoints]

#ASH17: The big loser in CAR-T, Juno is making a bid to seize the fast lane to frontrunner status [EndPoints]

5.9 AACR

Number of Seamless Clinical Trials in Oncology Has Risen Recently [AACR]

NCI-MATCH Reaches Central Patient-screening Goal [AACR]

5.9.10 AACR - colorectal

New Colorectal Cancer Test Could Detect Early Cancer-causing Genetic Biomarkers with High Degree of Sensitivity [AACR]

Colorectal Cancers May Mutate to Escape Immune System Detection in Many Ways [AACR]

5.9.11 AACR - SNC

Safety of gene therapy for brain tumours tested in early trial [Cancer Research UK]

Gene Therapy Shows Early Efficacy Against Recurrent Brain Cancer [AACR]

5.9.7 AACR - divers

Tazemetostat Shows Early Promise for Children with Certain Relapsed or Refractory Solid Tumors [AACR]

5.9.9 AACR - immunothérapies

Computer programme could predict if immunotherapy will work [Cancer Research UK]

A Non-invasive Computational Imaging Approach May Help Predict Response to Immunotherapy [AACR]

6. Lutte contre les cancers

It is Time for a Concerted European Approach to Defeat Cancer [ESMO]

U.S. experts set research agenda to meet 'Cancer Moonshot' goals [Reuters]

6.1 Observation

Infertility in women could be sign of increased cancer risk, study finds [The Telegraph]

Heartburn Drugs Tied to Stomach Cancer Risk [NY Times]

6.11 Patients

She said she had cancer, and neighbors opened their wallets. Then a stranger’s email raised questions [STAT]

The responses to the “cancer drugs scandal” must fully involve patients—an essay by Tessa Richards [BMJ]

I was meant to be dead by 40 – but I’m still here, living in cancer limbo [The Guardian]

6.4 Médico-éco

I’ve been a cancer nurse for over 30 years – things have never been so bad [The Guardian]

Cancer competition drives robot surgery, clinic closures in UK [Reuters]

6.5 Médecines alternatives

Alternative cancer therapies: the potential impact on survival [Cancer Research UK]

FDA warns companies marketing unproven products, derived from marijuana, that claim to treat or cure cancer [FDA]

Cancer charity hires 'fake news' nurse to warn patients off bogus cures [The Telegraph]

F.D.A. Warns Companies Against Claims That Marijuana Cures Diseases [NY Times]

6.7 DMP, Big Data & applis

Johns Hopkins Partnering with Other Institutions to Create a National Center for Health Data [Johns Hopkins]

The Evolution of Patient Diagnosis [JAMA]

6.8 Communication

Breast Cancer Is Serious. Pink Is Not. [NY Times]

6.9 Controverses

Plans to promote German research excellence come under fire [Nature]